Trump demands drug companies lower prices in U.S. and raise them in other countries

The U.S. White House has issued letters to 17 major pharmaceutical companies, demanding they raise drug prices in other countries and reinvest the increased revenue to lower U.S. prices within 60 days. Citing U.S. drug prices as three times higher than other nations, the administration seeks “most favored nation” pricing for U.S. Medicaid patients and threatens to use “every tool” despite limited explicit legal authority. This directive, following a prior executive order, also encourages direct-to-consumer sales, but contrasts with simultaneous threats of up to 200% tariffs on pharmaceuticals, which could disrupt supply chains given the U.S. reliance on foreign active pharmaceutical ingredients.

Analysis

The U.S. administration has created significant regulatory uncertainty for 17 major pharmaceutical companies by demanding they implement a "most favored nation" pricing model for U.S. Medicaid patients within 60 days. This directive, which pressures firms like Pfizer, Merck, and Johnson & Johnson to raise international prices to subsidize U.S. price cuts, lacks explicit legal authority and relies on ambiguous threats to "deploy every tool," creating a volatile environment. The policy is further complicated by a contradictory threat of imposing tariffs as high as 200% on pharmaceutical inputs. Given that an estimated 88% of active pharmaceutical ingredients for the U.S. market are produced abroad, such tariffs would drastically increase production costs and risk severe supply chain disruptions, directly undermining the stated goal of lowering domestic drug prices. While the administration also encourages a direct-to-consumer sales model, which some executives like Roche's CEO see as a viable path for cost reduction, this potential long-term benefit is overshadowed by the immediate and conflicting pressures from trade and pricing policies.

Key Decisions for Investors

• Investors should anticipate heightened volatility for the 17 named pharmaceutical stocks (including ABBV, PFE, LLY, JNJ) due to significant near-term regulatory and headline risk stemming from the White House's demands.
• Carefully monitor any developments regarding the proposed 200% tariffs, as their implementation represents a material threat to the sector's entire supply chain and profitability, potentially leading to cost inflation and drug shortages.
• While the "most favored nation" pricing demand faces legal and practical hurdles, the dual threat of pricing action and tariffs creates a decidedly negative outlook, warranting a cautious or defensive stance on the sector until policy clarity emerges.
• Assess individual companies' geographic revenue distribution and supply chain diversification, as firms less reliant on U.S. sales or with more resilient, domestically-oriented manufacturing may be better insulated from these specific political pressures.